Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer

被引：0
|
作者：
O'Rourke, Kate
机构：
来源：
CANCER | 2022年 / 128卷 / 05期
关键词：
D O I：
10.1002/cncr.34102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 938
页数：1
相关论文
共 50 条
  • [1] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
    Li, Bob T.
    Smit, Egbert F.
    Goto, Yasushi
    Nakagawa, Kazuhiko
    Udagawa, Hibiki
    Mazieres, Julien
    Nagasaka, Misako
    Bazhenova, Lyudmila
    Saltos, Andreas N.
    Felip, Enriqueta
    Pacheco, Jose M.
    Perol, Maurice
    Paz-Ares, Luis
    Saxena, Kapil
    Shiga, Ryota
    Cheng, Yingkai
    Acharyya, Suddhasatta
    Vitazka, Patrik
    Shahidi, Javad
    Planchard, David
    Janne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03): : 241 - 251
  • [2] Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
    Vathiotis, Ioannis A.
    Bafaloukos, Dimitrios
    Syrigos, Konstantinos N. N.
    Samonis, George
    CANCERS, 2023, 15 (04)
  • [3] Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
    Janne, P.
    Goto, Y.
    Kubo, T.
    Ninomiya, K.
    Kim, S. -W.
    Planchard, D.
    Ahn, M. -J.
    Smit, E. F.
    de Langen, A. J.
    Perol, M.
    Pons-Tostivint, E.
    Novello, S.
    Hayashi, H.
    Shimizu, J.
    Kim, D. -W.
    Pereira, K.
    Cheng, F. -C.
    Taguchi, A.
    Cheng, Y.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S148
  • [4] Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
    Cai, Qi
    You, Shuhui
    Huang, Jinglong
    Gong, Caifeng
    Zhang, Wen
    Zhou, Aiping
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [5] DESTINY-Lung01 Trial Investigators Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
    Sharayah, Ahmad
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (06) : 749 - 750
  • [6] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Cobbina, Enoch
    Cheng, Shen
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer: A Reminder That More Is Not Always Better
    Hoe, Hui Jing
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (31) : 4849 - +
  • [8] Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study
    Smit, Egbert F.
    FUTURE ONCOLOGY, 2024, 20 (27) : 1961 - 1971
  • [9] Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)
    Pitiyarachchi, Omali
    Tan, Aaron C.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02)
  • [10] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
    Janne, Pasi A.
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    De langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345